Aldosterone Lab Results: Normal Reference Range vs. Functional Optimal

The core question this page answers

The useful question is not "is my aldosterone normal" but "does my aldosterone, interpreted alongside renin, posture, sodium status, and symptoms, point toward a condition that needs confirmatory testing." A single aldosterone value sitting inside a lab's reference interval can still be consistent with primary aldosteronism if renin is suppressed, and a value near the low end of "normal" can still be consistent with adrenal insufficiency if posture and sodium intake were not standardized at the draw. Reference ranges answer a population question. The ARR and clinical context answer the patient's question.

What aldosterone does and why the number matters

Aldosterone is the body's primary mineralocorticoid, produced in the zona glomerulosa of the adrenal cortex. It acts on the kidneys to retain sodium and excrete potassium, directly affecting blood pressure and fluid balance. Excess aldosterone drives hypertension, hypokalemia, and cardiovascular tissue damage; deficiency causes salt wasting, low blood pressure, and hyperkalemia.

The renin-angiotensin-aldosterone system (RAAS) governs aldosterone secretion through a feedback loop responsive to blood volume, distal sodium delivery, and potassium concentration (Bollag 2014). Posture, sodium intake, time of day, and several common medication classes all shift a measured aldosterone value. A result of 4 ng/dL may be physiologic in someone lying supine on a high-sodium diet, or it may reflect adrenal insufficiency in someone standing upright and sodium-depleted. The number by itself is not a diagnosis.

Standard reference ranges: what "normal" actually means

Reference ranges for aldosterone vary meaningfully between laboratories because each derives its own interval from its assay platform and reference population rather than from a single universal standard. A 2016 evaluation of a specialty immunoassay platform used to establish population reference intervals for aldosterone and renin illustrates why: the numeric cutoffs depend on the assay method and the cohort used to build them, which is one reason two labs can publish different "normal" ranges for the same hormone (Manolopoulou et al., 2016). In practice this means a result of, say, 18 ng/dL can be flagged high by one lab and unflagged by another, and the flag itself is less informative than the ARR.

"Normal" on a lab report means the result falls within roughly the middle 95% of the lab's reference population. It does not mean the result is optimal for a given patient's cardiovascular health, electrolyte balance, or symptom profile. A patient with an aldosterone of 2 ng/dL may be technically "normal" by some lab ranges yet report orthostatic symptoms, fatigue, and salt cravings worth investigating further, particularly if renin is also low.

Functional optimal ranges: a different clinical lens, not a validated cutoff

Some functional and integrative practitioners apply a narrower target window, often described as roughly 6 to 12 ng/dL for an upright morning sample. This range does not appear in the Endocrine Society guideline on primary aldosteronism or in any comparable regulatory or society document reviewed for this page (Endocrine Society, 2016). It is best understood as a clinical pattern-recognition heuristic rather than an evidence-graded target, and readers should not use it to self-interpret a lab result or to decide that a guideline-normal value requires treatment.

The distinction matters most at the margins. A patient with aldosterone of 2.5 ng/dL and renin of 0.5 ng/mL/hr has a low ARR and a "normal" aldosterone by most standard lab ranges; a clinician using the functional heuristic might flag the absolute value as low and investigate adrenal reserve or sodium status further. A patient at 22 ng/dL with suppressed renin might fall inside a lab's stated reference range yet screen positive for primary aldosteronism under Endocrine Society ARR criteria. Neither framework is inherently wrong. Standard ranges are built to flag population-level pathology; the functional heuristic is an unvalidated attempt to describe a narrower zone of subjective wellbeing. The clinical question, and the presence or absence of hypertension, hypokalemia, or symptoms, should determine which lens is applied, and this determination belongs to a clinician, not a single lab value.

The aldosterone-to-renin ratio: the actual screening tool

The ARR, not the isolated aldosterone value, is the tool the Endocrine Society recommends for screening. The 2016 guideline recommends ARR screening for patients with sustained blood pressure above 150/100 mmHg, resistant hypertension (uncontrolled on three drugs), hypertension with spontaneous or diuretic-induced hypokalemia, hypertension with an adrenal incidentaloma, or a family history of early-onset hypertension or stroke before age 40 (Endocrine Society, 2016).

A positive screen is generally defined as an ARR above 30 (aldosterone in ng/dL divided by plasma renin activity in ng/mL/hr) combined with an aldosterone above 15 ng/dL, though a 2019 analysis of cut-off points for the ARR in primary aldosteronism found that the optimal threshold varies with the assay method and population studied, and cautioned against treating any single cutoff as universally valid (Song et al., 2019). Readers whose result sits near a threshold should ask their clinician which assay and cutoff their lab uses rather than assuming a fixed number applies everywhere.

The ARR is sensitive but not specific. False positives occur with beta-blocker use (which suppresses renin more than aldosterone), renal impairment, and advanced age. False negatives occur with ACE inhibitors, ARBs, diuretics, and dihydropyridine calcium channel blockers. The guideline recommends withdrawing mineralocorticoid receptor antagonists for at least four weeks and other interfering medications for at least two weeks before testing, when stopping the medication is safe for that patient (Endocrine Society, 2016).

High aldosterone: primary aldosteronism and cardiovascular risk

Primary aldosteronism (PA) is estimated to affect roughly 5 to 10% of hypertensive patients overall and a higher share of those with resistant hypertension (Rossi et al., 2006). A cross-sectional comparison found higher rates of atrial fibrillation, myocardial infarction, and heart failure among PA patients compared with blood-pressure-matched hypertensive controls, suggesting that aldosterone excess carries cardiovascular risk beyond what blood pressure elevation alone explains (Milliez et al., 2005). Mechanistically, aldosterone is thought to promote myocardial fibrosis and endothelial dysfunction through mineralocorticoid receptor activation in tissues outside the kidney, as described in reviews of aldosterone's non-renal effects.

The two main PA subtypes are aldosterone-producing adenoma (APA), typically treated surgically, and bilateral adrenal hyperplasia (BAH), typically managed with mineralocorticoid receptor antagonists such as spironolactone or eplerenone (Endocrine Society, 2016). An international outcomes analysis of adrenalectomy for unilateral PA (the PASO consortium) found complete clinical cure, meaning normal blood pressure without medication, in a minority of patients, with a larger share showing significant clinical improvement rather than complete cure; biochemical cure rates (normalization of the aldosterone excess itself, distinct from blood-pressure cure) were substantially higher (Williams et al., 2017). This distinction between biochemical and clinical outcomes matters for setting expectations before surgery and should be discussed directly with the treating endocrinologist or surgeon.

Secondary hyperaldosteronism, in which both aldosterone and renin are elevated, occurs in renovascular hypertension, congestive heart failure, cirrhosis, and nephrotic syndrome. Elevated renin is what separates it from primary aldosteronism.

Low aldosterone: hypoaldosteronism and its consequences

Hyporeninemic hypoaldosteronism (a form of type 4 renal tubular acidosis) is a recognized cause of hyperkalemia disproportionate to the degree of kidney function loss, seen in diabetic nephropathy, mild-to-moderate chronic kidney disease, and with chronic NSAID use, as described in classic nephrology literature. Patients typically present with hyperkalemia, mild non-anion-gap metabolic acidosis, and relatively preserved sodium balance.

Primary adrenal insufficiency (Addison's disease) causes combined deficiency of cortisol and aldosterone. Guideline material describes a low population prevalence and characteristic symptoms of orthostatic hypotension, salt craving, hyperkalemia, and hyponatremia (Bornstein et al., 2016). Fludrocortisone is the standard mineralocorticoid replacement, titrated by a treating clinician using serum electrolytes and blood pressure response rather than a fixed dose (Bornstein et al., 2016). A review of adrenal insufficiency management describes monitoring mineralocorticoid replacement using serum sodium, potassium, and plasma renin activity, generally aiming to avoid a suppressed renin, which would suggest over-replacement (Bancos et al., 2015). This monitoring principle, keeping renin from being frankly suppressed, is a useful working idea for clinicians even though it is not identical to the informal functional optimal range discussed above.

Evidence boundary: what is established, what is plausible, what is not established

Established: The ARR is the recommended first-line screening test for primary aldosteronism in at-risk patients, per the Endocrine Society guideline. Standard reference ranges for aldosterone vary by laboratory and assay. Primary aldosteronism carries cardiovascular risk beyond blood pressure alone. Adrenalectomy for a unilateral aldosterone-producing adenoma produces high rates of biochemical cure, though clinical (blood pressure) cure rates are lower.

Plausible but unproven at the population level: That a narrower "functional optimal" aldosterone band (commonly cited as roughly 6 to 12 ng/dL) correlates with fewer symptoms of fatigue or dysautonomia. This idea is used in some integrative practice but has not been validated in a guideline-graded trial or reference-range study reviewed here.

Not established: That a single aldosterone value, without an accompanying renin and clinical context, can reliably diagnose either aldosterone excess or deficiency. That specific micronutrient or supplement protocols raise or normalize aldosterone in a clinically meaningful, trial-proven way; the supportive evidence for such interventions on aldosterone-specific endpoints is limited and should not be treated as equivalent to guideline-recommended therapy.

Testing protocol: how to get an interpretable result

Sample collection conditions are the single biggest determinant of whether an aldosterone or ARR result is usable. The Endocrine Society guideline specifies:

Medication timing. Spironolactone and eplerenone are typically discontinued at least 4 weeks before testing; ACE inhibitors, ARBs, beta-blockers, and dihydropyridine calcium channel blockers are typically withdrawn at least 2 weeks before testing, only when a clinician judges this safe for that patient. Verapamil slow-release and alpha-blockers are generally used for blood pressure control during washout because they have less effect on the ARR.

Sodium status. An unrestricted sodium diet for at least 3 days before testing is recommended, since sodium restriction independently raises both aldosterone and renin.

Posture. For a standard upright sample, the patient is typically ambulatory for at least 2 hours before the draw and seated for 5 to 15 minutes just before collection.

Timing. Morning draws (roughly 8 to 10 AM) are standard given aldosterone's circadian pattern.

Potassium. Hypokalemia suppresses aldosterone secretion and can produce a false-negative ARR; correcting potassium before testing is recommended.

Confirmatory testing after a positive ARR screen may include oral sodium loading with 24-hour urine aldosterone, intravenous saline infusion, or fludrocortisone suppression testing, per the Endocrine Society guideline (Endocrine Society, 2016).

Choosing which aldosterone framework applies to your result

When to retest and what to do next

Retesting aldosterone is reasonable if the original sample was drawn under suboptimal conditions (wrong posture, interfering medication not withdrawn, uncorrected hypokalemia) or if clinical suspicion for PA remains high despite a negative screen; the Endocrine Society guideline specifically cautions against excluding PA based on a single ARR result when pre-test probability is high (Endocrine Society, 2016).

For patients with confirmed PA, adrenal CT is the usual first imaging step, and adrenal vein sampling (AVS) is used in surgical candidates to determine whether excess secretion is unilateral or bilateral. A randomized outcome-based comparison of CT-guided versus AVS-guided treatment decisions found similar blood pressure outcomes at one year, though AVS remains the guideline-preferred approach in appropriate candidates because incidental non-functioning adrenal nodules can make CT interpretation unreliable (Dekkers et al., 2016).

For patients whose aldosterone is inside a standard reference range but symptoms persist, a reasonable next step is to ensure the sample was drawn correctly, check renin alongside a basic metabolic panel, and discuss with a clinician whether repeat testing or a broader endocrine workup is warranted, rather than adjusting behavior or supplements based on the informal functional range alone.

Seek urgent care for symptoms of a possible adrenal crisis (severe vomiting, profound weakness, confusion, very low blood pressure) in anyone with known or suspected adrenal insufficiency, and for severe hyperkalemia symptoms (muscle weakness, palpitations, chest pain) regardless of the suspected cause. These situations require emergency evaluation, not a routine follow-up lab.